Longeveron: Funding, Investors & Team (Oct 2026)
Longeveron is a company in the field of life sciences that focuses on creating biological solutions for aging and diseases related to aging. The company's main product under investigation is Lomecel-B™, a therapy made from medicinal signaling cells (MSC) obtained from the bone marrow of healthy adult donors. Lomecel-B™ has the potential to offer various benefits such as promoting blood vessel development, facilitating tissue regeneration, reducing inflammation, and aiding in tissue repair. Due to these qualities, Lomecel-B™ can be utilized in the treatment of a diverse range of diseases. Currently, Longeveron is conducting clinical trials for Lomecel-B™ in three specific areas: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Aging-related Frailty.
Longeveron has raised $51.1M across 6 funding rounds on record, the most recent an undisclosed round of $30.0M announced in Mar 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Longeveron Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Longeveron Funding Rounds
Longeveron raised $4.0M in an undisclosed round announced in Oct 2023.
2 months later, an undisclosed round of $2.4M was announced in Dec 2023.
4 months later, an undisclosed round of $5.3M was announced in Apr 2024.
2 months later, an undisclosed round of $4.4M was announced in Jun 2024.
1.2 years later, an undisclosed round of $5.0M was announced in Aug 2025.
7 months later, an undisclosed round of $30.0M was announced in Mar 2026.
Longeveron Founders and Leadership Team
Contact details for the Longeveron team: 1 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Longeveron Funding Compared to Other Biotechnology Startups
Longeveron's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Longeveron in Biotechnology and Miami
Companies Similar to Longeveron
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Longeveron Funding FAQs
What does Longeveron do?
Longeveron is a company in the field of life sciences that focuses on creating biological solutions for aging and diseases related to aging. The company's main product under investigation is Lomecel-B™, a therapy made from medicinal signaling cells (MSC) obtained from the bone marrow of healthy adult donors. Lomecel-B™ has the potential to offer various benefits such as promoting blood vessel development, facilitating tissue regeneration, reducing inflammation, and aiding in tissue repair. Due to these qualities, Lomecel-B™ can be utilized in the treatment of a diverse range of diseases. Currently, Longeveron is conducting clinical trials for Lomecel-B™ in three specific areas: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Aging-related Frailty.
How much funding has Longeveron raised?
Longeveron has raised $51.1M across 6 rounds on record. The most recent is an undisclosed round of $30.0M announced in Mar 2026.
When did Longeveron last raise funding?
Longeveron's most recent funding round on record is an undisclosed round of $30.0M, announced in Mar 2026.
Who founded Longeveron?
FundedIQ lists Donald Soffer (Founder), Joshua Hare (Founder), Steve Willard (Founder) at Longeveron.
Where is Longeveron headquartered?
Longeveron is based in Miami, Florida, United States.
How many employees does Longeveron have?
Longeveron is in the 11-50 employee band.
How does Longeveron's funding compare to other Biotechnology startups?
Longeveron's latest round of $30.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Longeveron Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Longeveron is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.